Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 60

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Pα+ February 2026 Psychedelic Bill Roundup

Navigating Colorado’s Regulated Psychedelic Model: Lessons From the Front Lines

The State of the Psychedelic Industry & Open Questions (Video)

Psilocybin for OCD: Terence Ching on Lessons from Yale’s Randomised Trials

Pα+ Psychedelic Bulletin #220: New State Bills; Congressional Mentions; Published Psilocybin, DMT, and Methylone Studies; RAND Polling Reveals 23% of Americans Support Legal Psilocybin...

Pα+ Psychedelic Patent Analysis: A Mebufotenin Melee (Dec ’23 & Jan...

PT488 – The Cost of War: Veterans’ Mental Health and Government...

Pα+ Psychedelic Bulletin #156: Canada’s First Published Psilocybin Trial; University of...

PT487 – Interoception, Healing Through Connection, and Learning to Trust Our...

Pα+: Day 2 Dispatch from ‘Advancing Psychedelic Clinical Study Design’, Hosted...

Opinion: How Ayahuasca Could Change You

Natural Medicine Advisory Bulletin #8.1: Recommendation Round-up

Natural Medicine Advisory Bulletin #8: January 2024

Pα+: Dispatch from ‘Advancing Psychedelic Clinical Study Design’, Hosted by the...

PT486 – 5-MeO-DMT, Somatic Release, and Creating Context for Spirituality

Load more

EDITOR PICKS

Pα+ February 2026 Psychedelic Bill Roundup

Navigating Colorado’s Regulated Psychedelic Model: Lessons From the Front Lines

The State of the Psychedelic Industry & Open Questions (Video)

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©